In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reformulation has Ruled in Neurology Dealmaking--Until Now

Executive Summary

The big deals in other therapeutic areas focus on novel molecules, in neurology, most focus on formulations of existing molecules. There just hasn't been a lot of novel material that's piqued the interest of licensees, at least in part because of the risk of developing novel neurology compounds. But as Windhover's Therapeutic Alliances: Neuroscience conference showed, much of the new, licensable pipeline is very novel indeed.

You may also be interested in...

Cost, Risk and Scientific Conservatism Dramatically Limit the Dealmaking for Heart Medicines.

Although cardiovascular drugs represent the biggest category in pharmaceutical sales, dealmaking has been surprisingly slight compared to other therapeutic areas. The low activity level reflects minimal progress in creating novel medicines and the clinical risk and cost innovators face.

Pfizer Sets New Biotech M&A Record

Pfizer's proposed acquisition of Rinat Neuroscience is the costliest private biotech purchase yet--it paid $500 million in cash for the CNS play. What's more extraordinary still is that the most valuable asset at Rinat is pre-clinical.

Cephalon: Can Spec Pharma do R&D?

Cephalon's 2005 dealmaking flurry illustrates the growing influence of in-house R&D on a firm whose success to date has come from in-licensing. Its challenge will be selling investors pipeline potential, as well as earnings growth.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts